9.95
price up icon7.68%   0.71
after-market 시간 외 거래: 9.90 -0.05 -0.50%
loading
전일 마감가:
$9.24
열려 있는:
$9.2
하루 거래량:
3.09M
Relative Volume:
1.09
시가총액:
$1.13B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-2.7949
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
+10.31%
1개월 성능:
-4.51%
6개월 성능:
-27.48%
1년 성능:
-76.70%
1일 변동 폭
Value
$9.00
$10.23
1주일 범위
Value
$9.00
$10.23
52주 변동 폭
Value
$6.36
$47.45

다인 테라 Stock (DYN) Company Profile

Name
명칭
Dyne Therapeutics Inc
Name
전화
(781) 786-8230
Name
주소
1560 TRAPELO ROAD, WALTHAM
Name
직원
192
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
DYN's Discussions on Twitter

DYN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
DYN
Dyne Therapeutics Inc
9.95 1.31B 0 -294.51M -244.42M -3.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

다인 테라 Stock (DYN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-24 개시 Bernstein Mkt Perform
2025-06-11 재개 Raymond James Outperform
2025-06-02 재개 Oppenheimer Outperform
2025-05-29 개시 Evercore ISI Outperform
2025-03-12 개시 BMO Capital Markets Outperform
2025-03-07 개시 Scotiabank Sector Outperform
2024-12-13 개시 Robert W. Baird Outperform
2024-11-26 개시 RBC Capital Mkts Outperform
2024-10-24 다운그레이드 JP Morgan Overweight → Neutral
2024-05-21 재확인 Chardan Capital Markets Buy
2024-04-30 개시 Morgan Stanley Overweight
2024-02-20 개시 H.C. Wainwright Buy
2023-02-27 업그레이드 Raymond James Outperform → Strong Buy
2023-02-15 개시 Oppenheimer Outperform
2023-01-26 개시 Guggenheim Buy
2022-07-20 개시 Chardan Capital Markets Buy
2022-07-12 개시 Raymond James Outperform
2020-10-12 개시 JP Morgan Overweight
2020-10-12 개시 Jefferies Buy
2020-10-12 개시 Piper Sandler Overweight
2020-10-12 개시 Stifel Buy
모두보기

다인 테라 주식(DYN)의 최신 뉴스

pulisher
Jul 24, 2025

Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News

Jul 22, 2025
pulisher
Jul 21, 2025

Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 18, 2025

Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat

Jul 18, 2025
pulisher
Jul 16, 2025

Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com

Jul 15, 2025
pulisher
Jul 12, 2025

Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance

Jul 12, 2025
pulisher
Jul 11, 2025

Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks

Jul 10, 2025
pulisher
Jul 08, 2025

RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Dyne Therapeutics shares rise 2.08% after-hours following RBC's price target cut to $25. - AInvest

Jul 07, 2025
pulisher
Jul 05, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 05, 2025
pulisher
Jul 04, 2025

(DYN) Trading Report - news.stocktradersdaily.com

Jul 04, 2025
pulisher
Jul 04, 2025

Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 04, 2025
pulisher
Jul 03, 2025

ATTENTION DYN Shareholders: Lost Money on Dyne Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Petri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debt - The Business Journals

Jul 03, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Announces Closing of Public Offering of Common - GuruFocus

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics' $230M Capital Injection: A Strategic Gamble in Rare Neuromuscular Disorders? - AInvest

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Closes $230 Million Public Offering of Common Stock - Quiver Quantitative

Jul 02, 2025
pulisher
Jul 02, 2025

Dyne Therapeutics Announces Closing of Public Offering of - GlobeNewswire

Jul 02, 2025
pulisher
Jul 02, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 02, 2025
pulisher
Jul 01, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 01, 2025
pulisher
Jul 01, 2025

Shareholders Alert: Investigation Into Dyne Therapeutics, Inc. (DYN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 01, 2025
pulisher
Jul 01, 2025

Dyne Therapeutics (DYN) Launches $200 Million Public Offering - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Jul 01, 2025

다인 테라 (DYN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):